Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 2,103 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 2,103 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the completion of the sale, the chief marketing officer now owns 15,609 shares of the company’s stock, valued at $3,605,522.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $247.00 on Friday. The firm’s fifty day moving average is $157.89 and its two-hundred day moving average is $164.23. The firm has a market cap of $31.24 billion, a PE ratio of -92.16 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd grew its position in shares of Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after acquiring an additional 77,307 shares during the period. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the period. Robeco Institutional Asset Management B.V. grew its position in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the period. Westpac Banking Corp grew its position in shares of Alnylam Pharmaceuticals by 59.8% in the 4th quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 566 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Alnylam Pharmaceuticals by 630.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after acquiring an additional 22,580 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. SVB Leerink upped their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a report on Tuesday. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a report on Monday. Finally, Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a report on Tuesday. Eight research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $245.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.